About Zinc finger protein 1 homolog
Zinc finger protein 1 homolog (ZFP1) is a protein
from Homo sapiens identified by UniProt accession
Q6P2D0, 407 residues long.
MolForge cross-references it against 0 known binders and
23 disease associations.
Target properties
| Protein name | Zinc finger protein 1 homolog |
| UniProt accession | Q6P2D0 |
| Gene | ZFP1 |
| Organism | Homo sapiens |
| Length | 407 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (23)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.39
- body height · score 0.35
- BMI-adjusted waist circumference · score 0.29
- vital capacity · score 0.26
- high density lipoprotein cholesterol measurement · score 0.26
- eosinophil percentage of leukocytes · score 0.24
- forced expiratory volume · score 0.21
- sitting height measurement · score 0.12
- eosinophil percentage of granulocytes · score 0.08
- laryngeal squamous cell carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6P2D0-F1 | alphafold | PREDICTED | 65.58 | — |
Amino-acid sequence (407 residues)
MNKSQGSVSF TDVTVDFTQE EWEQLDPSQR ILYMDVMLEN YSNLLSVEVW KADDQMERDH RNPDEQARQF LILKNQTPIE ERGDLFGKAL NLNTDFVSLR QVPYKYDLYE KTLKYNSDLL NSNRSYAGKQ TDECNEFGKA LLYLKQEKTH SGVEYSEYNK SGKALSHKAA IFKHQKIKNL VQPFICTYCD KAFSFKSLLI SHKRIHTGEK PYECNVCKKT FSHKANLIKH QRIHTGEKPF ECPECGKAFT HQSNLIVHQR AHMEKKPYEC SECGKTFAQK FELTTHQRIH TGERPYECNE CAKTFFKKSN LIIHQKIHTG EKRYECSECG KSFIQNSQLI IHMRTHTGEK PYECTECGKT FSQRSTLRLH LRIHTGEKPY ECSECGKAFS RKSRLSVHQR VHIGEKP
Explore Zinc finger protein 1 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets